Updated:
Fortrea
Fortrea launched in mid-2023, carved from Labcorp’s Drug Development business in a tax-free spinoff that created a fully independent public company.
Fortrea
Fortrea launched in mid-2023, carved from Labcorp’s Drug Development business in a tax-free spinoff that created a fully independent public company. Thomas Pike, a former Quintiles executive with decades of CRO experience, stepped in as CEO at separation. The transaction distributed Fortrea shares to existing Labcorp shareholders, establishing a standalone clinical-services enterprise from day one. The Durham, North Carolina headquarters anchors the largest CRO cluster in the world, placing the firm inside the heart of the clinical-research corridor. The company runs Phase I–IV clinical trials, patient-access programs, and real-world evidence studies across more than 90 countries. Its business model is service-based and asset-light: pharmaceutical sponsors and biotech clients contract Fortrea to design protocols, manage sites, and submit regulatory filings. Unlike Discovery-stage CROs, Fortrea’s revenue is weighted toward late-phase trial execution, where multi-year contracts generate predictable fee-for-service revenue. Institutional investors track the company’s book-to-bill ratio as a forward indicator, a dynamic the firm inherited from its publicly reporting Labcorp lineage. Named pharmaceutical relationships span top-20 global drugmakers, though individual client contracts remain confidential. Fortrea had not publicly reported formal assets under management as of early 2026, and the company does not maintain an investment portfolio or make direct venture commitments. In September 2023, the firm opened a dedicated office in the Research Triangle Park region to support its standalone clinical operations infrastructure. The spinoff structure means the company’s financial position is transparent through SEC filings, with quarterly earnings reports disclosing revenue, backlog, and margin targets. As of the firm’s most recent public filing, net book-to-bill ratios have remained above 1.0x, signaling sustained demand for its clinical-trial services. Fortrea is structurally distinct among major CROs: it is the only firm in the sector created as a pure-play public entity through a corporate separation, not a private-equity roll-up or a strategic acquisition. The spinoff relieved the clinical business from Labcorp’s diagnostic-lab capital allocation constraints, while exposing it directly to public-market incentives. Pike’s leadership team operates with a decentralized site-network model where regional clinical managers hold trial-execution authority, a governance architecture that reduces protocol-approval bottlenecks compared to centralized CRO counterparts. Disciplined cost management remains the observable strategic priority — a posture reflected in the firm’s early standalone earnings calls.
General information
Firm type
other
Year founded
2023
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Principals
Thomas Pike
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at Fortrea?
Fortrea does not operate an investment portfolio or in-house allocation function comparable to a family office, endowment, or asset manager. Strategic capital decisions — mergers, acquisitions, capital expenditures for laboratory infrastructure — flow through CEO Thomas Pike and the board of directors. As a publicly traded corporation, Fortrea is governed by a board elected by shareholders and subject to SEC disclosure requirements.
How is Fortrea related to Labcorp?
Fortrea was created through a tax-free spinoff from Labcorp in mid-2023, separating Labcorp’s Drug Development segment into an independent public company. Existing Labcorp shareholders received Fortrea shares through a pro-rata distribution at the time of separation. The two firms now operate as fully independent entities with no common ownership or operational overlap (per the Form 10 registration statement filed with the SEC, 2023).
What type of entity is Fortrea — does it function as a family office or an investment vehicle?
Fortrea is a publicly traded contract research organization, not a family office, asset manager, or investment partnership. It is correctly classified as a commercial enterprise that sells clinical-development services to biopharmaceutical sponsors. Family offices and institutional allocators encounter Fortrea as a potential equity investment, not as a fund manager or co-investment partner.
What does Fortrea actually do for revenue?
Fortrea designs and manages clinical trials on behalf of pharmaceutical, biotechnology, and medical-device sponsors. The company’s services span protocol writing, site selection, patient recruitment, data management, biostatistics, and regulatory submission support. Most revenue comes from multi-year, fee-for-service contracts tied to Phase II and Phase III trial execution, with additional contributions from real-world evidence studies and decentralized trial services.
Where does Fortrea operate geographically?
Fortrea maintains clinical-trial operations in more than 90 countries. Its operational footprint includes North America, Western and Eastern Europe, Asia-Pacific, Latin America, and the Middle East, reflecting the global site networks required by large pharmaceutical clients. The corporate headquarters is in Durham, North Carolina, with additional operational hubs established post-spinoff.
What investment stages or asset classes does Fortrea target?
Fortrea does not invest in portfolio companies, funds, or asset classes. As a contract research organization, it is a service provider to drug developers — not an allocator of financial capital. The company may, from time to time, acquire smaller CROs or technology platforms to expand its service capabilities, but these are corporate M&A transactions, not principal investment activities.
Does Fortrea maintain a philanthropic structure or foundation?
There is no publicly documented philanthropic foundation directly tied to Fortrea Holdings Inc. as of the data cutoff. The company's community engagement typically takes the form of clinical-trial diversity initiatives and patient-access programs, which are integrated into the commercial business rather than housed in a separate charitable entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: